Mark A. Velleca - 21 Jan 2026 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
PRESIDENT & CEO, Director
Signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
Issuer symbol
BDTX
Transactions as of
21 Jan 2026
Net transactions value
$0
Form type
4
Filing time
23 Jan 2026, 16:05:05 UTC
Previous filing
31 Jan 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Velleca Mark A. PRESIDENT & CEO, Director C/O BLACK DIAMOND THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE /s/ Brent Hatzis-Schoch, Attorney-in-Fact 23 Jan 2026 0001706847

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDTX Stock Option (Right to Buy) Award $0 +600,000 $0.000000 600,000 21 Jan 2026 Common Stock 600,000 $2.57 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.